| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | BLA | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
BLA Submission example | BLA | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
BLA Submission example | BLA | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Dyne Therapeutics, Inc.$23.42
-0.85 (-3.5%)
C 41Pipeline Score Richly Valued Biotech · Clinical
Market Cap
2.87 B
EPS
-3.23
P/E Ratio
-
Value Trade
27.61 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
100.89 M
Operating CF
-144.92 M
Total Assets
1.08 B
Total Liabilities
214.90 M
Equity
865.05 M
D/E Ratio
12,345
-2.66 %
Week
-9.77 %
1 Month
15.49 %
3 Month
-12.76 %
6 Month
-3.93 %
5 Year
-23.11 %
All Time
Cash Data
Cash Position
972.16 M
Monthly Burn
48.31 M
Runway
18.3 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
1.51 M
52 Week Range
8.06 - 25
% held by Insiders
19.06 %
% held by Institutions
93.68 %
Enterprise Value
2.07 B
Total Shares
165.14 M
Short %
14.99 %
Float Shares
148.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dyne Therapeutics, Inc.
264Total events
17Upcoming
54Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 17
Event history 247
Jun 17, 2026
▲Debt Royalty FinancingCorporate
Expanded debt facility of up to $400 million with Hercules Capital; $50 million funded at closing
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference 2026 meetings
Jun 3, 2026
Jun 3, 2026
▲Enrollment Completezeleciment basivarsenTrial
Completion of enrollment in registrational expansion cohort of ACHIEVE trial
myotonic dystrophy type 1 (DM1)source ↗
May 20, 2026
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference fireside chat
May 13, 2026
◆Oral PresentationPresentation
Oral presentation on robust and widespread MAPT silencing in CNS of mice and NHP with TfR1-mediated oligonucleotide delivery
Tauopathiessource ↗
May 11, 2026
▲Pre BLA Meetingz-rostudirsenFDA Meeting
Positive pre-BLA meeting completed with FDA for z-rostudirsen
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
Q2 2026
◆Enrollment Completezeleciment basivarsenTrial
Complete enrollment in ACHIEVE Registrational Expansion Cohort
myotonic dystrophy type 1source ↗
Q2 2026
◆NDA SubmissionDYNE-251Regulatory Filing
Submission for U.S. Accelerated Approval on track for Q2 2026
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
Q2 2026
◆BLA Submissionz-rostudirsenRegulatory Filing
Planned BLA submission for U.S. Accelerated Approval of z-rostudirsen
Duchenne muscular dystrophy (exon 51 skip amenable)source ↗
Q2 2026
◆Trial Initiationz-rostudirsenTrial
Initiation of global confirmatory Phase 3 trial of z-rostudirsen
Duchenne muscular dystrophy (exon 51 skip amenable)source ↗
Drug Pipeline Intelligence
C41
Pipeline Score $222M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 59%
Small Cap (rank 375 of 911)
Percentile RankDyne Therapeutics, Inc. carries a moderate pipeline score (41/100), with $341M risk-adjusted pipeline value, led by DYNE-251 in Duchenne Muscular Dystrophy (DMD) (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DYNE-251 Small molecule | Duchenne Muscular Dystrophy (DMD) | Phase 1 | NCT05524883 | 53% | $186M | ACTIVE NOT_RECRUITING | 86 | AVERAGE | B (64) | Nov 1, 2029 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
z-rostudirsen | Duchenne muscular dystrophy (DMD) | Phase 1/2 | 2026-03-09 | improvement in cardiopulmonary function over 24 months | Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Read More | |
z-rostudirsen | Duchenne muscular dystrophy (DMD) | Phase 1/2 | 2026-03-09 | improvement in cardiopulmonary function over 24 months | Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Read More | |
z-rostudirsen | Duchenne muscular dystrophy (DMD) | Phase 1/2 | 2026-03-09 | improvement in cardiopulmonary function over 24 months | Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DYN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DYN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DYNDyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics has appointed Barry Greene to its Board of Directors as part of its strategy to transition into a commercial biotechnology company. Greene brings over 30 years of experience in the biopharmaceutical industry, which includes leadership roles at Sage Therapeutics and Alnylam Pharmaceuticals. His expertise is expected to enhance Dyne's capabilities in delivering innovative therapies for neuromuscular diseases.
Read more →DYNDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →DYN▲ +6.3%on this newsshared move
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Dyne Therapeutics has expanded its debt facility with Hercules Capital, increasing its borrowing capacity by up to $400 million. This amendment includes an immediate funding of $50 million and additional funds contingent on achieving specific milestones. The company aims to leverage this capital to advance its clinical programs for Duchenne muscular dystrophy and myotonic dystrophy, with potential U.S. launches in the next two years.
Read more →DYNDyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial for z-basivarsen, targeting myotonic dystrophy type 1 (DM1). A total of 71 participants were enrolled, with topline data expected in Q1 2027. The company aims for a potential U.S. launch in H1 2028, pending FDA approval.
Read more →DYNDyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
Read more →DYNDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 20, 2026
Dyne Therapeutics has granted inducement equity awards to 17 new employees as part of their hiring process, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards include stock options and restricted stock units, which are designed to incentivize long-term commitment to the company. Dyne is dedicated to developing therapies for genetically driven neuromuscular diseases.
Read more →DYN▲ +10.3%on this newsshared move
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Read more →DYNDyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Read more →DYNDyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics reported strong financial results for Q1 2026, highlighting a positive pre-BLA meeting with the FDA for z-rostudirsen, which is on track for BLA submission in Q2 2026. The company also presented promising data from the DELIVER trial in DMD and achieved enrollment targets for the ACHIEVE trial of z-basivarsen. Despite a net loss of $120.9 million, Dyne maintains a robust cash position to support its operations.
Read more →DYNDyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
Dyne Therapeutics announced it will present preclinical data at the ASGCT 2026 Annual Meeting, showcasing its FORCE platform's capability to cross the blood-brain barrier and achieve significant MAPT RNA knockdown in the central nervous system. The presentation will occur on May 13, 2026, with insights into optimizing the platform for enhanced CNS delivery. This builds on previous studies supporting the platform's efficacy.
Read more →DYNDyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Read more →DYN▲ +19%on this news· ran to +33% by day 1
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics has announced positive results from the DELIVER trial of z-rostudirsen for Duchenne muscular dystrophy (DMD). The latest analyses show significant improvements in cardiopulmonary function over 24 months, expanding on previous findings of enhanced muscle function. These results highlight the potential of z-rostudirsen to address critical health issues in DMD patients.
Read more →DYN▲ +19%on this news· ran to +33% by day 1
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics has initiated the Phase 3 HARMONIA trial to evaluate z-basivarsen in myotonic dystrophy type 1 (DM1). The trial will enroll approximately 150 participants and assess efficacy, safety, and tolerability over 48 weeks. The primary endpoint is the five times sit to stand test, with secondary endpoints including various muscle function assessments. This trial is aligned with FDA protocols and aims to support traditional approval in the U.S.
Read more →DYNDyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting positive topline results from its Phase 1/2 DELIVER trial for z-rostudirsen in Duchenne muscular dystrophy (DMD). The company is on track for a U.S. Accelerated Approval submission in Q2 2026, with a potential launch in Q1 2027. Dyne also reported a strong cash position of $1.1 billion, expected to sustain operations into 2028.
Read more →DYNDyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
Read more →DYNSparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
Sparrow Pharmaceuticals has appointed Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti brings over 35 years of experience in the biopharmaceutical industry and is expected to contribute significantly as Sparrow advances its lead candidate, clofutriben, for type 2 diabetes. His expertise is seen as a validation of Sparrow's innovative approach to treating metabolic dysfunction.
Read more →DYNDyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
Dyne Therapeutics has received Orphan Drug designation in Japan for zeleciment basivarsen (DYNE-101) aimed at treating myotonic dystrophy type 1 (DM1). The drug is currently being evaluated in the Phase 1/2 ACHIEVE clinical trial, which has shown promising results in improving muscle function. This designation highlights the need for effective treatments for this rare disease.
Read more →DYNAdvancing Clinically Validated Platform Toward Commercialization 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | JANUARY 2026 Forward-Looking Statements & Disclaimer This presentation contains forward-looking statements
Dyne Therapeutics showcased its clinically validated FORCE platform for targeted delivery in various neuromuscular diseases at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted positive topline results from a registrational cohort in Duchenne muscular dystrophy (DMD) and expressed potential for commercial launch by Q1 2027. Dyne maintains a robust cash position, estimated at approximately $1.1 billion, ensuring its ability to further its pipeline and clinical efforts. However, the company also noted inherent risks and uncertainties in advancing its product candidates through clinical trials and regulatory processes.
Read more →DYN▲ +7%on this newsshared move
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Read more →DYNDyne Therapeutics Appoints Vikram Karnani to Board of Directors
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
Read more →DYNDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Read more →DYN▼ -16.9%on this newsshared move
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
Dyne Therapeutics has announced the pricing of an upsized public offering of common stock, consisting of approximately 18.98 million shares at a price of $18.44 per share, aiming to raise gross proceeds of $350 million. The offering is set to close on or about December 11, 2025, subject to customary conditions. Notably, Dyne has also provided underwriters with a 30-day option to purchase additional shares. This offering comes as the company continues its developments in therapeutics for genetic neuromuscular diseases.
Read more →DYN▲ +9.5%on this newsshared move
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics announced positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen for Duchenne muscular dystrophy. The trial's Registrational Expansion Cohort met its primary endpoint, showing a significant increase in dystrophin levels and functional improvements across multiple clinical measures. The company plans to submit for U.S. Accelerated Approval in Q2 2026, aiming for a potential launch in Q1 2027.
Read more →DYN▲ +9.5%on this newsshared move
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Read more →DYN▲ +9.5%on this newsshared move
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
Dyne Therapeutics will announce topline results from the Registrational Expansion Cohort of the Phase 1/2 DELIVER trial for DYNE-251 on December 8, 2025. An investor conference call and webcast will be held at 8:00 a.m. ET, with a press release issued beforehand. The event will be accessible via the company's website.
Read more →DYN▼ -12.9%on this news
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics reported its Q3 2025 financial results, highlighting significant progress in its clinical trials for DMD and DM1. The company anticipates topline data from the DELIVER trial in December 2025, which may support U.S. Accelerated Approval for z-rostudirsen. Additionally, z-basivarsen's enrollment in the ACHIEVE trial is now expected to conclude in early Q2 2026. Despite a net loss increase, Dyne maintains a strong cash position to support its upcoming product launches.
Read more →DYN▲ +6.8%on this news· ran to -19% by day 3shared move
Dyne Therapeutics to Present at Upcoming Investor Conferences
Dyne Therapeutics, a clinical-stage company, has announced its participation in upcoming investor conferences. The presentations will be accessible via live webcast and will focus on their advancements in therapies for genetically driven neuromuscular diseases. The company aims to improve functional outcomes for patients with conditions such as myotonic dystrophy and Duchenne muscular dystrophy.
Read more →DYN▲ +10.3%on this news
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics has announced additional one-year data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 (DM1). The data show significant improvements in function and strength, supported by patient-reported outcomes. These findings suggest that z-basivarsen may offer broad benefits for DM1 patients, enhancing their daily functioning.
Read more →DYNDyne Therapeutics Appoints Brian Posner to its Board of Directors
Dyne Therapeutics has appointed Brian Posner to its Board of Directors, bringing 35 years of leadership experience. His appointment comes as the company prepares to transition into a fully integrated biotechnology firm, aiming to commercialize its first product by 2027. Posner's expertise in investment and governance is expected to enhance the company's strategic direction.
Read more →DYN▼ -5.9%on this newsshared move
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics has been granted Orphan Drug designation for DYNE-251 in Japan, targeting Duchenne muscular dystrophy (DMD) with specific mutations. The ongoing DELIVER trial has shown sustained functional improvements over 18 months. This designation complements existing approvals in the U.S. and Europe, highlighting the drug's potential in addressing unmet needs in DMD treatment.
Read more →DYNDyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to its investigational drug DYNE-251 for treating Duchenne muscular dystrophy (DMD). This designation is based on promising data from the DELIVER clinical trial, which aims to provide significant functional improvements for patients. The company anticipates data from the trial by late 2025 and a potential BLA submission in early 2026.
Read more →DYN▼ -6.4%on this news
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned comm
Dyne Therapeutics reported its second quarter 2025 financial results, highlighting an extended cash runway into Q3 2027, which supports their upcoming drug approvals. The company is advancing its investigational therapies DYNE-101 and DYNE-251 toward potential submissions for U.S. Accelerated Approval in 2026. Additionally, Dyne has reported a substantial net loss and rising R&D expenses, signaling ongoing investment in their clinical programs as they prepare for potential commercial launches in 2027.
Read more →DYNDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics has successfully closed its public offering of 27,878,788 shares at $8.25 each, raising around $230 million. The offering included additional shares purchased by underwriters and was conducted under a previously filed SEC registration statement. The company focuses on developing therapies for genetically driven neuromuscular diseases.
Read more →DYN▼ -8.8%on this newsshared move
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
Dyne Therapeutics has announced the pricing of a public offering of 24,242,425 shares at $8.25 each, aiming to raise $200 million. The offering is expected to close around July 2, 2025, and includes an option for underwriters to purchase additional shares. This funding will support Dyne's development of therapies for neuromuscular diseases.
Read more →DYNDyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
Read more →DYN▼ -21.4%on this news
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - Based on Type C meeting and new data, Dyne submitted revised ACHIE
Dyne Therapeutics has announced that the FDA has granted Breakthrough Therapy Designation for its treatment DYNE-101, aimed at myotonic dystrophy type 1 (DM1). Following a Type C meeting with the FDA, Dyne has submitted an updated trial protocol that emphasizes the use of vHOT as a primary endpoint for Accelerated Approval. The company's ongoing ACHIEVE trial aims to enroll 60 participants as part of its registrational expansion cohort. Positive long-term data from the trial supports the potential clinical benefit of DYNE-101 in DM1 patients.
Read more →DYNDyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
Read more →DYNDyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
Read more →DYN▲ +20.2%on this news
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following recei
Dyne Therapeutics reported its first quarter 2025 financial results and highlighted recent business developments, including a Type C meeting with the FDA regarding DYNE-101 for DM1. The company has initiated registrational cohorts for pivotal trials of DYNE-101 and DYNE-251, aiming for U.S. Accelerated Approval submissions in 2026. Despite a substantial net loss in Q1 and rising R&D expenses, Dyne's cash position remains strong at $677.5 million. Additionally, the leadership team has been reinforced to enhance execution of strategic initiatives.
Read more →DYNDyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Read more →DYN▲ +5.1%on this news· ran to +25% by day 3
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
Read more →DYNDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Read more →DYNDyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Read more →DYNDyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
Read more →DYNDyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
Read more →DYNDyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Received FDA Fast Track Designation for DYNE-101 in DM1 - - Full enrollment of Registrational Expansion Cohor
Dyne Therapeutics announced its financial results for Q4 and full year 2024, highlighting key developments in their clinical programs. The FDA awarded Fast Track designation for DYNE-101 aimed at treating myotonic dystrophy type 1 (DM1), with plans for a Registrational Expansion Cohort in the ACHIEVE trial. Dyne anticipates completing full enrollment by mid-2025 to support Accelerated Approval submissions in early 2026 for both DYNE-101 and DYNE-251, targeting patients with defects in specific neuromuscular diseases. However, the company reported increased net losses compared to the previous year, emphasizing the financial challenges during their transition.
Read more →DYNDyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Read more →DYNDyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Read more →DYNDyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Read more →DYN▼ -31.1%on this news
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.
Dyne Therapeutics has reported new clinical data from its Phase 1/2 ACHIEVE trial for DYNE-101 in patients with myotonic dystrophy type 1 (DM1), demonstrating substantial functional benefits and a favorable safety profile. The company plans to initiate a global Registrational Expansion Cohort to support a submission for U.S. Accelerated Approval, potentially by the first half of 2026. Additionally, Dyne is advancing the development of DYNE-251 for Duchenne muscular dystrophy (DMD), with regulatory submissions expected in early 2026. The simultaneous progress in both areas emphasizes Dyne's commitment to addressing unmet medical needs in neuromuscular diseases.
Read more →DYN▼ -31.1%on this newsshared move
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Read more →DYNDyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
Read more →DYNDyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early Janua
Dyne Therapeutics has reported its third quarter 2024 financial results, highlighting the FDA's clearance of the IND application for DYNE-101 for DM1. In addition, the company announced it is enrolling a registrational cohort for DYNE-251 in the DELIVER trial for Duchenne muscular dystrophy. A strong cash position of $723.7 million allows Dyne to advance its clinical programs, with significant trial data expected in early January 2025. However, the company also reported a substantial net loss during the quarter, raising concerns about its financial trajectory amidst ongoing development.
Read more →DYNDyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases
Read more →DYN▼ -5.4%on this news
Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference
Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference
Read more →DYNDYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation on behalf of Dyne Therapeutics stockholders regarding potential violations of federal securities laws and misleading statements made by the company. This follows a recent press release where Dyne announced positive clinical data from a trial related to Duchenne muscular dystrophy, contrasted by the resignation of key executives. The resulting stock price decline of 30.7% has raised concerns about the company's transparency and governance. Investors who have suffered losses are encouraged to reach out to the firm for assistance.
Read more →DYN▼ -30.7%on this news
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE- 251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - In
Dyne Therapeutics announced promising new data from the Phase 1/2 DELIVER trial of DYNE-251, demonstrating unprecedented levels of dystrophin expression and significant functional improvements in Duchenne muscular dystrophy (DMD) patients. The company intends to initiate registrational cohorts by the end of 2024, with further updates on their registration pathway expected. The trial has shown dose-dependent improvements and suggests a potential shift in treatment for DMD. The data highlight the effectiveness of DYNE-251 in both ambulant and non-ambulant patients with specific mutations.
Read more →DYN▼ -30.7%on this news
Dyne Therapeutics Announces Key Leadership Appointments
Dyne Therapeutics Announces Key Leadership Appointments
Read more →DYNDyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Read more →DYNDyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Recent Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrated Compelling Impact on Ke
Dyne Therapeutics reported its Q2 2024 financial results and provided updates on its clinical trials, particularly the ACHIEVE and DELIVER trials for DYNE-101 and DYNE-251, respectively. Both trials have shown promising data, indicating significant improvements in disease biomarkers and patient functionality. The company also announced a successful public offering that has bolstered its financial capacity, allowing operations to continue into the latter half of 2026. Additionally, Dyne is engaging with regulatory bodies to expedite the approval processes for its lead programs.
Read more →DYNDyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
Read more →DYNDyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
Read more →DYNDyne Therapeutics to Present at Jefferies Global Healthcare Conference
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
Read more →DYN▼ -7.8%on this news
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
Dyne Therapeutics has announced the pricing of a public offering for 10,500,000 shares of its common stock at $31.00 per share, aimed at raising $325.5 million in gross proceeds. The offering will close around May 24, 2024, subject to standard conditions. The proceeds are intended to support the development of innovative therapeutics for genetically driven muscle diseases, underscoring Dyne's commitment to advancing its clinical programs. Various financial institutions are involved as joint book-running managers and co-managers for this offering.
Read more →DYN▲ +27.8%on this newsshared move
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional En
Dyne Therapeutics has announced positive clinical data from the Phase 1/2 trials of its therapies DYNE-101 for myotonic dystrophy type 1 (DM1) and DYNE-251 for Duchenne muscular dystrophy (DMD). The ACHIEVE trial revealed a mean splicing correction and improvements in muscle strength and function for patients with DM1. Meanwhile, the DELIVER trial indicated a significant increase in dystrophin expression for DMD patients, exceeding existing treatment benchmarks. Both treatments showed promising safety profiles, and the company is actively pursuing expedited approval pathways.
Read more →DYN▲ +27.8%on this newsshared move
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
Read more →DYNDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Secon
Dyne Therapeutics has reported financial results for the first quarter of 2024, highlighting its strong cash position of $453.5 million, projected to fund operations through 2025. The company anticipates additional clinical data from its ACHIEVE and DELIVER trials for DYNE-101 and DYNE-251 in the latter half of 2024, with plans to initiate registrational cohorts by the end of the year. Despite a net loss of $65.6 million, the management remains optimistic about the future of its pipeline and the potential impact of its FORCE platform on patients with muscle diseases.
Read more →DYN▲ +6.4%on this news
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Read more →DYN▲ +6.4%on this news
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
Read more →DYN▼ -7.7%on this newsshared move
Dyne Therapeutics Announces CEO Transition
Dyne Therapeutics Announces CEO Transition
Read more →DYNDyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
Read more →DYN▼ -6.6%on this news
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstra
Dyne Therapeutics reported positive initial clinical data from its ACHIEVE trial in DM1 and DELIVER trial in DMD, validating the FORCE platform. A successful public offering raised $345 million, extending the cash runway through 2025. The company aims to optimize dosing regimens and report additional data from its trials later in 2024. However, financial results indicated a significant net loss, raising concerns about future profitability.
Read more →DYNDyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
Read more →DYNDyne Therapeutics to Present at February Investor Conferences
Dyne Therapeutics to Present at February Investor Conferences
Read more →DYN▼ -7.4%on this news
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Read more →DYN▲ +31.3%on this newsshared move
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
Dyne Therapeutics has announced the pricing of a public offering of 17,150,000 shares at $17.50 each, aiming to raise approximately $300.1 million. The offering is set to close around January 9, 2024, pending standard conditions. The funds raised will support Dyne's commitment to developing innovative treatments for genetically driven muscle diseases, utilizing their proprietary FORCE platform. This development is poised to enhance their pipeline products for serious muscle diseases.
Read more →DYN▲ +13.1%on this news· ran to +48% by day 1shared move
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE Platform in Developing Therapeutics for Rare Muscle Disea
Dyne Therapeutics announced promising initial results from its ACHIEVE and DELIVER trials, assessing DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy, respectively. Both trials yielded positive data regarding safety and efficacy, particularly showing dose-dependent improvements in splicing correction and dystrophin expression. Dyne aims to advance these findings, with future data expected in the second half of 2024, while pursuing expedited regulatory pathways to provide treatments for these rare muscle diseases.
Read more →DYNDyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
Read more →DYN▲ +14.6%on this news
Dyne Therapeutics to Present at November Investor Conferences
Dyne Therapeutics to Present at November Investor Conferences
Read more →DYN▲ +10.6%on this news
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones - Initial ACHIEVE and DELIVER Data to be Presente
Dyne Therapeutics has made significant advancements in its Phase 1/2 clinical trials, ACHIEVE and DELIVER, for treatments targeting myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Both trials have completed enrollment in their respective cohorts, and over 300 doses have been administered with favorable safety profiles observed. Initial data from both trials is expected to be presented around the J.P. Morgan Healthcare Conference in early January 2024. Financial results show a net loss of $60.2 million for the third quarter of 2023, indicating increased R&D investment.
Read more →DYNDyne Therapeutics to Present at October Investor Conferences
Dyne Therapeutics to Present at October Investor Conferences
Read more →DYN▼ -5.5%on this news
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Read more →DYNDyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Read more →DYNDyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD Durin
Dyne Therapeutics reported its second quarter 2023 financial results, highlighting significant advancements in its clinical trials for DYNE-101 and DYNE-251. The company is on track to provide initial clinical data from these trials in the latter half of 2023, which has raised expectations among stakeholders. While the cash reserves remain strong at $207.7 million, the company also reported an increase in net loss and rising research and development expenses. Overall, the company continues to advance its therapeutic solutions while managing significant financial challenges.
Read more →DYNDyne Therapeutics to Present at Jefferies Healthcare Conference
Dyne Therapeutics to Present at Jefferies Healthcare Conference
Read more →DYN▼ -7.6%on this news
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
Read more →DYNDyne Therapeutics' Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
Dyne Therapeutics' Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
Read more →DYNDyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During
Dyne Therapeutics reported its financial results for Q1 2023 and highlighted significant progress in its clinical trials. The company is on track to release initial data from the ACHIEVE and DELIVER trials, which focus on treatments for DM1 and DMD, respectively, in the latter half of 2023. Dyne continues to engage with the scientific community, showcasing its FORCE platform at major conferences. Despite a widening net loss and increased R&D expenses, the company maintains a strong cash position to support its operations through 2024.
Read more →DYNDyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
Read more →DYNDyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS
Read more →DYNDyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Read more →DYNDyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
Read more →DYN▲ +5.1%on this newsshared move
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights - Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Tria
Dyne Therapeutics has reported its fourth quarter and full year 2022 financial results, showcasing significant progress in advancing two programs into clinical trials. The company is preparing for important data readouts from its ongoing ACHIEVE trial of DYNE-101 for myotonic dystrophy type 1 and DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, both expected in the second half of 2023. Despite a strong cash position of $256 million projected to support operations until 2024, the company noted a rise in net loss year-over-year. The overall outlook remains optimistic as Dyne continues to engage with the muscle disease community and stakeholders.
Read more →DYNDyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Read more →DYN▲ +9.6%on this news
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights - DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights - DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 - WALTHAM, Mass., November 3, 2022 Dyne Therapeutics, Inc. (Nasdaq: DYN), a c
Read more →DYNDyne Therapeutics to Present at Investor Conferences in November
Dyne Therapeutics to Present at Investor Conferences in November
Read more →DYNDyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Read more →DYNDyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
Read more →DYN▼ -9.6%on this news
Dyne Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
Dyne Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
Read more →DYNDyne Therapeutics Highlights DM1 and DMD Clinical Programs During "Spotlight on the Clinic" Virtual Event
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During "Spotlight on the Clinic" Virtual Event
Read more →DYN▲ +5.3%on this news· ran to +35% by day 3
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Read more →DYN▲ +5.3%on this news· ran to +35% by day 3
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Read more →DYN▲ +5.3%on this news· ran to +35% by day 3
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Read more →DYNDyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development
Read more →DYN▲ +7.8%on this news
Dyne Therapeutics Announces "Breakthrough Article" Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
Dyne Therapeutics Announces "Breakthrough Article" Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
Read more →DYNDyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass., August 4, 2022 Dyne Therapeutics, In
Read more →DYN▲ +5.9%on this news· ran to +19% by day 3
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Read more →DYN▲ +17.2%on this news
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Read more →DYNDyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown
Read more →DYN▲ +6.8%on this news
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 - WALTHAM, Mass., May 2, 2022 Dyne Therapeutics, Inc.
Read more →DYNDyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights - Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 - - Initiation of Patien
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights - Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 - - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DY
Read more →DYNDyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
Read more →DYN▼ -12.6%on this news
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
Read more →DYN▼ -5.9%on this news
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Read more →DYNDyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy
Read more →DYNDyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights - Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne's Co-lead Candidates into the Clinic - - Investiga
Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights - Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne's Co-lead Candidates into the Clinic - - Investigational New Drug (IND) Submissions Anticipated for DYNE-251
Read more →DYNDyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
Read more →DYNDyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression
Read more →DYN▲ +6.5%on this newsshared move
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
Read more →DYNDyne Therapeutics to Present at Chardan's Virtual 5th Annual Genetic Medicines Conference
Dyne Therapeutics to Present at Chardan's Virtual 5th Annual Genetic Medicines Conference
Read more →DYNDyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress
Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress
Read more →DYNDyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights - On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - New I
Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights - On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - New In Vivo Data from DM1 and DMD Programs to be Presented at S
Read more →DYNDyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
Read more →DYNDyne Therapeutics Announces Chief Scientific Officer Transition
Dyne Therapeutics Announces Chief Scientific Officer Transition
Read more →DYNDyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
Read more →DYNDyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA
Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA
Read more →DYNDyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights - On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-R
Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights - On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-Resourced with Cash Runway Expected into the Second Half of
Read more →DYNNew Preclinical Data from Dyne Therapeutics' Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting
New Preclinical Data from Dyne Therapeutics' Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting
Read more →DYNDyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
Read more →DYNDyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights - Preclinical Data Further Validate FORCE Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Betwee
Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights - Preclinical Data Further Validate FORCE Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4'21 and Q4'22 - - Recent Appointments to Experienced L
Read more →DYNDyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
Read more →DYNDyne Therapeutics Announces Pricing of $168 Million Public Offering
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
Read more →DYNDyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
Read more →DYNDyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Read more →DYNDyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights - Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Con
Dyne Therapeutics Reports Third Quarter 2020 Financial Results and - Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and Duchenne Muscula
Read more →DYNDyne Therapeutics Announces Closing of Initial Public Offering
Dyne Therapeutics Announces Closing of Initial Public Offering
Read more →DYNDyne Therapeutics Announces Pricing of Initial Public Offering
Dyne Therapeutics Announces Pricing of Initial Public Offering
Read more →DYNDyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases
Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases
Read more →DYNDyne Therapeutics Appoints Susanna High as Chief Operating Officer
Dyne Therapeutics Appoints Susanna High as Chief Operating Officer
Read more →DYNDyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board
Dyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board
Read more →DYNDyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property
Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property
Read more →DYNDyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board
Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board
Read more →DYNDyne Therapeutics Demonstrates FORCE Platform's Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy
Dyne Therapeutics Demonstrates FORCE Platform's Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy
Read more →DYNDyne Therapeutics Appoints David Lubner to Board of Directors
Dyne Therapeutics Appoints David Lubner to Board of Directors
Read more →DYNDyne Therapeutics Expands Leadership Team with Key Hires
Dyne Therapeutics Expands Leadership Team with Key Hires
Read more →DYNDyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
Read more →DYNDyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer
Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer
Read more →DYNDyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors
Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors
Read more →DYNDyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
Read more →Competitive Position
How DYN ranks across every disease it competes inCompetitive Position is a premium feature
See how DYN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial